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Abstract
Background: The impact of final Thrombolysis in Myocardial Infarction (TIMI) flow in 
the infarct-related artery (IRA) on outcomes in non-ST-segment elevation myocardial infarc-
tion (NSTEMI) patients treated with percutaneous coronary intervention (PCI) is unknown. 
This study aimed to evaluate the impact of post-procedural TIMI flow in IRA on outcomes in 
NSTEMI patients undergoing percutaneous coronary revascularization.
Methods: We analyzed 2,767 patients with first NSTEMI from the Polish Registry of Acute 
Coronary Syndromes (PL-ACS) who underwent PCI. The patients were divided according to 
post-procedural culprit vessel TIMI (0–1: 90, 3.26%; 2: 61, 2.20%; 3: 2,616, 94.54%).
Results: The following mortality values were obtained in TIMI 0–1, 2, and 3 groups, respec-
tively: in-hospital, 12.22%, 13.11%, 1.72% (p < 0.0001); 1-month, 13.33%, 13.11%, 3.44% 
(p < 0.0001); 12-month, 15.56%, 16.39%, 6.50% (p < 0.0001); 36-month, 25.56%, 21.31%, 
13.91% (p = 0.0007). Mortality rates in patients with final TIMI 0–1 and 2 were not signifi-
cantly different. Optimal TIMI 3 was independently associated with baseline TIMI 2–3 (OR ± 
± 95% CI: 7.070 [4.35–11.82]), p < 0.0001; higher ejection fraction (1.30 [1.03–1.63]), 
p = 0.0038; and family history of coronary artery disease (2.83 [1.17–8.11]), p = 0.0294. Type C 
lesion, previous heart failure, and PCI without stenting independently predicted suboptimal 
TIMI 0–2.
Conclusions: Only achieving final TIMI 3 in IRA improves outcomes in NSTEMI patients 
treated with percutaneous coronary revascularization. The mortality rate of near-normal TIMI 
2 is comparable to that of TIMI 0–1 after PCI. (Cardiol J 2016; 23, 4: 402–410)
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Introduction
Registry data consistently show that non-ST-
-segment elevation myocardial infarction (NSTEMI) 
is the most common type of acute coronary syn-
drome [1]. Although in-hospital mortality is higher 
in patients with ST-segment elevation myocar-
dial infarction (STEMI) than among those with 
NSTEMI, long-term follow-up showed worse 
outcomes in NSTEMI patients [1, 2]. It is impor-
tant to determine factors worsening prognosis in 
this constantly increasing group of patients. In 
the era of interventional cardiology, percutaneous 
coronary revascularization is the main method of 
treatment, which has been demonstrated to im-
prove clinical outcomes [3, 4]. The goal of angio-
plasty is prompt restoration of normal flow in the 
infarct-related artery (IRA). Only post-procedural 
Thrombolysis in Myocardial Infarction (TIMI) 
flow grade 3 improves outcomes in patients with 
STEMI. Although it was shown that prognosis 
in patients with final TIMI flow grade 2 does not 
differ from that in patients with TIMI flow grade 
0–1, this conclusion was based on the results of 
outdated studies involving acute myocardial in-
farction (AMI) patients treated with thrombolytic 
therapy [5–7]. Thus, there is a paucity of data on 
the association between angiographic findings and 
clinical outcomes in patients with myocardial in-
farction (MI) without ST-segment elevation under-
going percutaneous coronary intervention (PCI). 
Moreover, clinical manifestations and predictors of 
suboptimal final coronary flow in this group, have 
not been investigated. Therefore, this study aimed 
to compare clinical characteristics, angiographic 
findings, and prognoses between PCI-treated 
NSTEMI patients with final TIMI 0–1 and 2 and 
those with final TIMI 3 using data from the Polish 
Registry of Acute Coronary Syndromes (PL-ACS).
Methods
Registry design
The PL-ACS registry is an ongoing, nation-
wide, multicenter, prospective, observational study 
of hospitalized patients with the entire spectrum 
of acute coronary syndromes (ACS) in Poland 
designed to collect information regarding epide-
miology, treatment, and outcomes. The method 
and results of the investigation of the first 100,193 
patients have been described [8]. Hospitals in all 
Polish regions were invited to enter the registry 
if they had a cardiology unit, an internal medicine 
unit, or if they hospitalized ≥ 10 patients with ACS 
per year. The detailed protocol with inclusion/ 
/exclusion criteria, methods and logistics, as well 
as definitions of all fields in the registry database 
was revised in May 2004 to comply with the Car-
diology Audit and Registration Data Standards [9]. 
Only patients with confirmed ACS were enrolled 
in the registry. If, within the acute phase of MI, 
a patient was transferred to another hospital, both 
hospitals were required to complete the case report 
form, and these hospitalizations were subsequently 
linked together and analyzed as 1 case. Data were 
collected by skilled physicians who were in charge 
of each patient. After initial internal checks for 
missing or conflicting data, values outside the ex-
pected ranges were implemented in the software. 
Once a month, collected data were sent to the Na-
tional Health Fund (NFZ), where they were cross-
checked with standard hospital reports. The NFZ 
then transferred the data to the central database in 
the Silesian Center for Heart Diseases in Zabrze, 
Poland, where further checks were conducted. 
All-cause mortality data, including exact dates of 
death were obtained from government database 
(NFZ — the only and obligatory health insurer for 
all citizens of Poland). The PL-ACS database was 
linked to the death database with the use of the 
personal identification number unique for every 
patient in the registry. Data on in-hospital com-
plications were collected by physicians who were 
taking care of the patients.
Patients
Between January and December 2008, a total 
of 4,125 patients with NSTEMI were treated with 
PCI and registered in the PL-ACS. The patients 
with prior MI, PCI, and coronary artery bypass 
grafting were excluded from the analysis. The 
remaining 2,767 patients were enrolled in this 
investigation.
Definition and treatment
To analyze the prognostic impact of final TIMI 
in IRA, patients were divided into three groups 
based on post-procedural TIMI: 0–1 (90 patients, 
3.26%), 2 (61 patients, 2.20%), and 3 (2,616 pa-
tients, 94.54%). TIMI grade flow is a scoring 
system from 0–3 referring to levels of coronary 
blood flow assessed during angiography: TIMI 0 
flow (no perfusion) refers to the absence of any an-
tegrade flow beyond a coronary occlusion; TIMI 1 
flow (penetration without perfusion) is a faint 
antegrade coronary flow beyond the occlusion, 
with incomplete filling of the distal coronary bed; 
TIMI 2 flow (partial reperfusion) is a delayed or 
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sluggish antegrade flow with complete filling of 
the distal territory; TIMI 3 is a normal flow which 
fills the distal coronary bed completely. NSTEMI 
was defined as (1) the absence of ST-segment 
elevation consistent with MI ≥ 2 mm in adjacent 
chest leads and ST-segment elevation ≥ 1 mm in 
2 standard leads and new left bundle branch block; 
and (2) positive cardiac necrosis markers. A coro-
nary artery was considered an IRA (culprit) based 
on angiographic features (confirmed or suspected 
thrombus, ruptured or ulcerated plaque, TIMI 
flow grade £ 2), electrocardiography recording, 
and echocardiographic findings. In-hospital and 
long-term mortalities were defined as death from 
all causes. Treatment strategy was considered 
invasive if coronary angioplasty was performed 
during the index hospitalization. Decisions related 
to treatment modalities (i.e., use of stents, intra-
aortic balloon pump, glycoprotein (GP) IIb/IIIa 
inhibitors, and angioplasty methods) were left to 
the discretion of attending physicians. This study 
was approved by appropriate institutional review 
boards.
Statistical analysis
Baseline characteristics were summarized as 
percentages for categorical variables and arith-
metic means ± standard deviations or medians 
and interquartile ranges for continuous variables. 
Continuous data distributions were analyzed with 
the Kolmogorov-Smirnov test. Baseline compari-
sons were made to test for differences between 
the groups using c2 tests for frequency data and 
ANOVA (or the Kruskal-Wallis test) with Tukey’s 
post-hoc method. To determine possible predictors 
of good TIMI flow after percutaneous transluminal 
coronary angioplasty (PTCA), variables were ana-
lyzed univariately. A multivariable logistic regres-
sion model was then developed using a directed 
stepwise approach with the following variables: 
age, sex, hypercholesterolemia, heart failure his-
tory, family history of coronary artery disease, left 
ventricular ejection fraction (LVEF), cardiogenic 
shock, GRACE score, pre-procedural TIMI (0–1 vs. 
2–3), time to PTCA (from onset), stent utilization, 
and type C lesion. Factors that met the signifi-
cance criteria of £ 0.05 were retained in the final 
model. Curves of cumulative probability of death 
were constructed according to the Kaplan-Meier 
method, and cumulative event rates were compared 
by Wilcoxon test. Hazard ratio (HR) estimates 
with 95% confidence interval (CI) were calculated 
using Cox proportional hazard regression analysis 
which included all variables with p-values in the 
univariate analyses < 0.01. The proportional 
hazards assumption was verified using graphi-
cal methods (log-log survivor function-by-time 
curve). All tests were 2-tailed. A p-value < 0.05 
was considered statistically significant. Statisti-
cal testing was performed using SAS version 9.2 
(SAS Institute, NC).
Results
Baseline characteristics  
(medical history and risk factors)
Table 1 compares the risk factors and base-
line characteristics among the 2,767 inclu-
ded patients. The patients with TIMI 0–1 and 
2 after PCI were older, but this difference was 
significant only between the TIMI 2 and TIMI 3 
groups (68.3 vs. 64.3 years, p < 0.05). Moreover, 
patients with post-PCI TIMI 0–1 had a signifi-
cantly higher frequency of previous heart failure 
than those with TIMI 3.
Clinical and electrocardiographic findings
The patients with post-procedural TIMI 3 had 
a remarkably higher incidence of sinus rhythm 
compared to TIMI 0–1 and 2 and a lower incidence 
of atrial fibrillation, the difference was significant 
only between TIMI 2 and TIMI 3 patients (Table 2). 
The Killip class ≥ 3 on admission was more com-
mon in patients with TIMI 0–1 after PCI than in 
TIMI 3 patients (7.78% vs. 2.67%, p = 0.0094), 
as was the number of patients with a GRACE risk 
score > 140 (47.78% vs. 35.42%, p = 0.0162). The 
TIMI 2 group showed intermediate values, but with 
no significant differences. 
Angiographic and echocardiographic findings
The non-optimal groups (0–1 and 2) had 
significantly higher frequencies of type C lesion 
and initial TIMI 0–1 in IRA than patients with 
TIMI 3 after PCI (Table 3). GP IIb/IIIa receptor 
antagonists were used more frequently in pa-
tients with TIMI £ 2. Patients with final TIMI 
0–1 had significantly lower LVEF compared 
to both TIMI 2 (44.2 ± 9.6 vs. 48.7 ± 10.8, 
p < 0.05) and TIMI 3 (44.2 ± 9.6 vs. 49.9 ± 9.8, 
p < 0.05) groups.
The post-procedural TIMI flow grades ac-
cording to baseline TIMI flow grades in IRA are 
presented in Figure 1.
Clinical outcome
Although in-hospital and long-term mortality 
rates did not differ between patients with final TIMI 
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Table 2. Clinical and electrocardiographic findings at admission.
TIMI 0–1 TIMI 2 TIMI 3 P P for pairwise TIMI
0–1 vs. 2 0–1 vs. 3 2 vs. 3
Dominant type of symptoms
Typical chest pain 92.2 (83) 91.8 (56) 93.0 (2434) 0.90 1.00 0.77 0.61
Dyspnea 4.4 (4) 4.9 (3) 2.0 (53) 0.053 1.00 0.12 0.13
Symptoms-to-PCI > 24 h 31.1 (28) 42.6 (26) 36.6 (959) 0.35 0.15 0.28 0.34
Symptoms-to-PCI > 72 h 5.6 (5) 3.3 (2) 3.7 (97) 0.565 0.70 0.39 1.00
Ischemic changes on ECG
ST-segment depression 46.7 (42) 34.4 (21) 45.2 (1183) 0.23 0.13 0.78 0.094
T-wave inversion 18.9 (17) 27.9 (17) 23.8 (623) 0.42 0.19 0.28 0.46
Heart rhythm
Sinus rhythm 87. 8 (79) 88.5 (54) 95.1 (2488) < 0.0001 0.89 0.006 0.033
Atrial fibrillation 7.8% (7) 11.5 (7) 4.4 (116) 0.014 0.44 0.13 0.021
Heart rate [bpm] 78.7 ± 19.7 76.4 ± 17.3 76.6 ± 16.2 0.49 0.66 0.46 0.99
Systolic BP [mm Hg] 134.4 ± 28.6 137.5 ± 23.2 139.5 ± 24.7 0.13 0.73 0.13 0.81
Diastolic BP [mm Hg] 79.2 ± 16.3 80.6 ± 14.9 81.8 ± 13.6 0.18 0.83 0.19 0.77
Killip class ≥ 3 7.8 (7) 3.3 (2) 2.7 (70) 0.016 0.15 0.009 0.27
GRACE score > 140 47.8 (43) 44.3 (27) 35.4 (927) 0.022 0.67 0.016 0.15
GRACE score [points] 144.5 ± 42.8 138 ± 36.8 131.4 ± 33.1 0.0005 0.47 0.0008 0.29
CK-MB [mg/dL]* 55.5  
[25.4–127.0]
44.0  
[37.0–97.1]
39.0  
[20–89.0]
0.0359 0.81 0.0394 0.11
Serum creatinine [mg/dL]* 0.98  
[0.84–1.20]
0.98  
[0.86–1.26]
0.97  
[0.81–1.17]
0.30 0.45 0.63 0.14
Admission glucose [mg/dL]* 129.0  
[96.0–164.9]
118.9  
[105–160.0]
113.0  
[98–143.0]
0.08 0.97 0.10 0.10
Data are presented as percentage (number) or mean ± standard deviation; *Median, with 25th; 75th percentiles range in brackets;  
BP — blood pressure, CK-MB — creatine kinase MB isoenzyme; ECG — electrocardiogram; PCI — percutaneous coronary intervention;  
TIMI — Thrombolysis in Myocardial Infarction
Table 1. Baseline characteristics and risk factors of study patients.
Parameters TIMI 0–1  
(n = 90)
TIMI 2  
(n = 61)
TIMI 3  
(n = 2616)
P P for pairwise TIMI 
0–1 vs. 2 0–1 vs. 3 2 vs. 3
Age [years] 66.8 ± 10.9 68.3 ± 11.7 64.3 ± 11.4 0.004 0.72 0.10 0.021
Female 32.2 (29) 34.4 (21) 35.2 (921) 0.84 0.78 0.56 0.90
Body mass index [kg/m2] 28.1 ± 6.8 28.4 ± 4.2 28.2 ± 6.7 0.98 0.98 0.99 0.99
Hypertension 64.4 (58) 72.1 (44) 71.7 (1876) 0.32 0.32 0.13 0.94
Diabetes mellitus 27.8 (25) 27.8 (17) 24.6 (645) 0.68 0.99 0.50 0.56
Hyperlipidemia 31.1 (28) 32.8 (20) 41.5 (1086) 0.06 0.83 0.049 0.17
Never smoking 47.8 (43) 47.5 (29) 40.9 (1070) 0.47 0.98 0.19 0.30
Previous angina 5.6 (5) 11.5 (7) 8.0 (210) 0.42 0.23 0.39 0.34
Family history CAD 3.3 (3) 6.6 (4) 9.2 (241) 0.13 0.44 0.056 0.48
Previous stroke 2.2 (2) 1.6 (1) 2.4 (63) 0.92 1.00 1.00 1.00
Heart failure 7.8 (7) 4.9 (3) 3.1 (80) 0.035 0.74 0.024 0.44
Peripheral vascular disease 5.6 (5) 3.3 (2) 3.8 (99) 0.67 0.70 0.39 1.00
Renal failure 4.4 (4) 11.5 (7) 5.6 (146) 0.13 0.12 0.824 0.08
Pulmonary disease 2.2 (2) 3.3 (2) 3.0 (79) 0.90 1.00 0.66 0.71
Data are presented as percentage (number) or mean ± standard deviation; CAD — coronary artery disease; TIMI — Thrombolysis in Myocar-
dial Infarction
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0–1 and 2 (Table 4), there were significant differ-
ences in in-hospital, 6-month, and 12-month mor-
tality rates and borderline-significant differences 
in 24- and 36-month mortality rates between TIMI 
2 and 3 patients. Survival curves after 3 years of 
observation showed significant difference between 
the TIMI 2 and 3 groups (Fig. 2).
As shown in Table 5, age, lower LVEF on 
admission, and higher GRACE risk score indepen-
dently correlated with 6-month and 1-year mor-
talities. Further investigation revealed additional 
factors predicting all-cause mortality, such as renal 
failure after 2 years and renal failure, as well as 
lower body mass index after 3 years.
Table 3. Angiographic, echocardiographic and laboratory findings.
TIMI 0–1 
(n = 90)
TIMI 2 
(n = 61)
TIMI 3 
(n = 2616)
P P for pairwise TIMI
0–1 vs. 2 0–1 vs. 3 2 vs. 3
Culprit lesion
Left anterior descending 
artery
26.7 (24) 29.5 (18) 34.7 (907) 0.21 0.70 0.12 0.40
Circumflex coronary artery 34.4 (31) 36.1 (22) 35.2 (922) 0.98 0.84 0.88 0.89
Right coronary artery 35.6 (32) 32.8 (20) 28.2 (737) 0.24 0.86 0.13 0.43
Left main coronary artery 2.2 (2) 1.6 (1) 1.8 (47) 0.78 1.00 0.68 0.93
Type C lesion 41.1 (37) 36.1 (22) 20.8 (544) < 0.0001 0.47 < 0.0001 0.015
Initial TIMI flow
TIMI 0–1 92.2 (83) 78.7 (48) 42.0 (1098) < 0.0001 0.016 < 0.0001 < 0.0001
TIMI 2 2.2 (2) 14.7 (9) 27.9 (732) < 0.0001 0.007 < 0.0001 0.022
TIMI 3 5.6 (5) 6.6 (4) 30.1 (786) < 0.0001 1.00 < 0.0001 < 0.0001
Multivessel coronary  
disease
56.7 (51) 49.2 (30) 47.7 (1249) 0.24 0.37 0.09 0.82
PCI without coronary  
stenting 
77.8 (70) 22.9 (14) 4.1 (106) < 0.0001 < 0.0001 < 0.0001 < 0.0001
LVEF [%] 44.2 ± 9.6 48.7 ± 10.8 49.9 ± 9.8 < 0.0001 0.046 0.0001 0.72
Anti-glycoprotein IIb/IIIa 12.2 (11) 19.7 (12) 5.7 (148) < 0.0001 0.21 0.009 < 0.0005
Clopidogrel 74% (82) 90.2% (55) 93.3% (2440) < 0.0001 0.17 < 0.0001 0.30
Ticlopidine 4.4% (4) 3.3% (2) 1.8% (47) 0.14 1.0 0.09 0.31
Data are presented as percentage (number) or mean ± standard deviation; LVEF — left ventricular ejection fraction; PCI — percutaneous 
coronary intervention; TIMI — Thrombolysis in Myocardial Infarction
Figure 1. Post-procedural Thrombolysis in Myocardial Infarction (TIMI) flow grades according to baseline TIMI flow 
grades.
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Figure 3. Independent predictors of postprocedural 
Thrombolysis in Myocardial Infarction (TIMI) flow in the 
infarct-related artery; HF — heart failure; LVEF — left ven-
tricular ejection fraction; CAD coronary artery disease.
Table 4. Short- and long-term mortality according to post-procedural Thrombolysis in Myocardial  
Infarction (TIMI) flow.
Mortality TIMI 0–1 
(n = 90) 
% (n)
TIMI 2 
(n = 61) 
% (n)
TIMI 3 
(n = 2616) 
% (n)
P P for pairwise TIMI
0–1 vs. 2 0–1 vs. 3 2 vs. 3
In-hospital 12.2 (11) 13.1 (8) 1.7 (45) < 0.0001 0.87 < 0.0001 < 0.0001
30-days 13.3 (12) 13.1 (8) 3.4 (90) < 0.0001 0.97 < 0.0001 < 0.001
6-months 15.6 (14) 16.4 (10) 6.5 (170) < 0.0001 0.89 < 0.001 < 0.01
12-months 15.6 (14) 18.0 (11) 8.5 (222) 0.0028 0.69 < 0.02 < 0.01
24-months 23.3 (21) 18.0 (11) 11.3 (295) 0.0007 0.43 < 0.001 0.10
36-months 25.6 (23) 21.3 (13) 13.9 (364) 0.0026 0.55 < 0.002 0.10
Figure 2. Kaplan-Meier 36-month survival curves ac-
cording to postprocedural Thrombolysis in Myocardial 
Infarction (TIMI) flow.
Table 5. Independent predictors of 6-month, 12-month, 24-month and 36-month all-cause mortality.
All-cause mortality Predictors Hazard ratio (95% CI) P
6-month Age 1.547 (1.087–2.200) 0.015
LVEF [%] 0.635 (0.498–0.810) 0.0003
GRACE 1.026 (1.018–1.034) < 0.0001
12-month Age 1.544 (1.152–2.069) 0.004
LVEF [%] 0.685 (0.554–0.846) 0.0005
GRACE 1.024 (1.017–1.031) < 0.0001
24-month Renal failure in history 2.049 (1.229–3.416) 0.006
Age 1.452 (1.138–1.853) 0.003
LVEF [%] 0.701 (0.582–0.845) 0.0002
GRACE 1.021 (1.015–1.028) < 0.0001
36-month Renal failure in history 2.336 (1.466–3.721) 0.0004
Age 1.463 (1.181–1.811) 0.0005
BMI 0.944 (0.904–0.986) 0.0101
LVEF [%] 0.634 (0.534–0.752) < 0.0001
GRACE 1.016 (1.011–1.022) < 0.0001
CI — confidence interval; BMI — body mass index; LVEF — left ventricular ejection fraction
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Clinical factors related  
to optimal TIMI 3 flow
After adjustment for all clinical and angi-
ographic characteristics, multivariate logistic 
regression demonstrated that optimal TIMI 3 
was independently associated with baseline 
TIMI 2–3 (OR ± 95 CI: 7.070 [4.35–11.82]), p < 
< 0.0001; higher LVEF on admission (1.30 [1.03–
–1.63]), p = 0.0038; and family history of coronary 
artery disease (2.83 [1.17–8.11]), p = 0.0294 
(Fig. 3). Type C lesion, heart failure in history, 
and PCI without stenting independently predicted 
suboptimal TIMI flow grade 0–2.
Discussion
Our study demonstrated the relationship 
between post-PCI TIMI flow grade and outcomes 
in patients with NSTEMI. The main findings can 
be summarized as follows: 1) Only achieving the 
final TIMI 3 in the IRA improves the outcomes 
in NSTEMI patients treated with percutaneous 
coronary revascularization; 2) Interestingly, the 
mortality rate in patients with near-normal TIMI 2 
was comparable to that in patients with TIMI 0–1 
after PCI; 3) Multivariable analysis revealed that 
type C lesion, heart failure history, and PCI with-
out stenting independently predicted the lack of 
optimal TIMI 3 after PCI.
To the best of our knowledge, this is the 
first study evaluating the clinical impact of final 
TIMI 2 on mortality in a large cohort of NSTEMI 
patients treated with PCI. The analysis shows no 
significant differences in hospital, 12-month, and 
36-month outcomes between patients with final 
TIMI 0–1 and 2. Furthermore, despite the lack 
of significant differences in the proportion of the 
GRACE risk score and incidence of symptoms of 
heart failure on admission between patients with 
post-procedural TIMI 2 and 3, the TIMI 2 group 
had significantly higher in-hospital, 6-month, and 
12-month mortalities. In an earlier study, patients 
with TIMI 2 had mortality rates intermediate to 
those of patients with TIMI 0–1 and TIMI 3 [10]. 
However, it is difficult to compare these results as 
the cited study included a heterogeneous group of 
STEMI, NSTEMI, and unstable angina patients, 
with NSTEMI patients constituting < 1/3 of the 
study population.
Interestingly, although differences in in-hospital 
and 1-year mortalities between patients with final 
TIMI 2 and 3 in IRA were significant, the 24-month 
and 36-month mortalities were only at the edge of 
statistical significance. An attempt to investigate this 
discrepancy with multivariable analysis of mortality 
revealed additional non-cardiac predictors of death 
identified during 24- and 36-month follow-up, such 
as renal failure and body mass index. This might be 
the main reason why statistically significant differ-
ences in mortality after 1 year were not observed. 
Because this study evaluated all-cause mortality, 
non-cardiac factors may have somewhat reduced the 
significance of the differences in all-cause mortality 
more than 1 year after NSTEMI.
Predictors of non-optimal coronary flow af-
ter percutaneous coronary revascularization in 
NSTEMI patients have not been described so far. 
In the present report, lower LVEF at presentation 
and previous left ventricular dysfunction were as-
sociated with a higher likelihood of poor final TIMI 
in IRA. Heart failure is associated with higher left 
ventricular end-diastolic pressure and reduced 
coronary perfusion pressure. These might cause 
more severe damage to microvascular circulation 
and interstitial edema, which in effect increases the 
risk of no-reflow syndrome. These findings are in 
agreement with the results of a previous study in-
volving STEMI patients, which demonstrated that 
low LVEF and advanced Killip class on admission 
were associated with higher prevalence of sub-
optimal TIMI 0–2 in STEMI patients undergoing 
primary angioplasty [10].
Type C lesion, determined according to the 
classification of American College of Cardiology/ 
/American Heart Association, independently pre-
dicted suboptimal final TIMI 0–1 and 2. It has been 
shown that type A lesion angioplasty is associated 
with 90% probability of success versus only 60% 
for type C [11]. In our report, the incidence of 
type C lesion was approximately 2-fold higher in 
TIMI 0–1 and 2 groups than in the TIMI 3 group. 
Furthermore, pre-procedural TIMI 0–1 was as-
sociated with a higher likelihood of suboptimal 
coronary flow after angioplasty. Initial total artery 
occlusion may reflect higher clot burden, the lack 
of spontaneous clot lysis, and higher amounts of 
thrombi and plaque material, leading to distal em-
bolization. These findings are in agreement with 
previous studies on patients with STEMI undergo-
ing PCI [12–14]. More advanced coronary lesions 
in combination with poorer initial flow in the IRA 
in TIMI 0–1 and 2 groups were responsible for the 
higher rate of revascularization failure.
Patients with post-procedural TIMI 0–1 and 
2 were older than those in the TIMI 3 group. 
Aging is associated with significant cardiovas-
cular structural changes, including endothelial 
and vascular smooth muscle dysfunction, diffuse 
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coronary atherosclerosis, increased coagulation 
factors, severe vascular calcification, and dis-
rupted microcirculation [15, 16], which makes the 
heart less resistant to ischemia and more prone to 
distal embolization during coronary angioplasty. 
According to the PAMI trial, age above 70 years 
is associated with suboptimal final coronary flow 
in STEMI patients [12].
In patients undergoing acute coronary inter-
vention following MI, distal embolization caused 
by thrombi and plaque material is an important 
additional mechanism, which may induce revascu-
larization failure. Downstream atheroembolization 
causes further blockage of structurally and func-
tionally changed cardiac arterioles and capillaries. 
It was reported that GP IIb/IIIa inhibitors reduce 
the clot burden at the epicardial coronary level and 
improve microvascular flow [17, 18]. In our study, 
GP IIb/IIIa receptor antagonists were used more 
frequently in TIMI 0–1 and 2 groups. It is known 
that intravenous administration of these antago-
nists not only blocks the final common pathway 
for platelet aggregation and prevents aggregation 
regardless of the initial activating stimulus, but 
could also enable lysis of an acutely formed platelet 
thrombus [19, 20]. Although proximal and distal 
mechanical protection devices and thrombectomy 
catheters may also prevent from distal emboliza-
tion, their effects on myocardial perfusion and clini-
cal outcome in patients with AMI remain unclear 
and controversial [21].
Apart from GP IIb/llla inhibitors administra-
tion, early dual antiplatelet and appropriate anti-
coagulant therapies may reduce clot burden and 
improve coronary flow. Previous studies based on 
STEMI population showed benefits from intracoro-
nary administration of adenosine or verapamil in 
prevention of revascularization failure by reducing 
microvascular reperfusion damage, but there is lack 
of data in NSTEMl [22, 23]. It has been reported 
that patients with metabolic syndromes [24] and 
hyperglycemia [25] are more likely to develop 
endothelial dysfunction and revascularization fail-
ure, therefore attention to blood sugar in patients 
with MI is important. Direct stenting compared 
with conventional stenting results in significantly 
greater rates of final TIMI3 flow in STEMI [26]. 
Further clinical research in pharmacological and 
procedural techniques improving acute angio-
graphic outcome in NSTEMl patients is needed 
together with industry involvement.
The precise mechanism by which final TIMI 
2 flow in NSTEMI patients undergoing primary 
PCI has impact on higher mortality is difficult 
to explain based on our research. Probably, not 
full restoration of coronary flow do not guarantee 
optimal myocardial perfusion and do not save as 
much as possible viable myocardium. On the other 
hand, higher incidence of final TIMI 2 flow among 
high-risk patients (older age, lower baseline TIMI 
flow, lower LVEF) suggests that TIMI 2 flow may 
be a surrogate marker of these high-risk groups. 
Taking all those observations into account, TIMI 2 
patients require more exact control and more ag-
gressive treatment after angioplasty.
Limitations of the study
The first limitation of this study is its retro-
spective nature. Furthermore, the culprit artery 
was determined by cardiologists in the catheter-
ization laboratories (using electrocardiographic, 
angiographic and echocardiographic findings), and 
the selection of the IRAs among the patients with 
multivessel disease might have differed between 
operators. Patients with previous MIs, percutane-
ous interventions, and coronary artery bypass 
grafting were excluded from the study because 
the culprit vessel in these subjects might have 
been incorrectly interpreted due to chronic total 
occlusion. Finally, there is a lack of data regarding 
detailed angiographic features, such as myocardial 
blush grade and thrombus burden.
Conclusions
This study demonstrates that achieving 
“near-normal” post-procedural TIMI flow grade 2 
does not improve prognosis in NSTEMI patients 
who underwent PCI. Only final TIMI flow grade 3 
should be considered an indication of successful 
revascularization. Patients with a history of heart 
failure, type C lesion in infarct-related coronary 
artery, and those treated without stenting are at 
a greater risk of suboptimal TIMI 0–2. Every ef-
fort should be made to achieve complete artery 
patency.
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